Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis

Mohamad A. Mouchli, Siddharth Singh, Edward Vincent Loftus, Jr, Lisa Allyn Boardman, Jayant Talwalkar, Charles B. Rosen, Julie K. Heimbach, Russell H. Wiesner, Bashar Hasan, John J. Poterucha, Kymberly D. Watt

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND: Patients with primary sclerosing cholangitis (PSC) may be at higher of risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for and long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients who underwent LT for PSC without cholangiocarcinoma from 1984-2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors and mortality from de novo malignancies after LT RESULTS: 293 patients were identified (mean age, 47±12 years; 63.3% males; 2.4% smoking at LT). Over a median of 11.5 years (range, 6.4-18.6), 64 patients (21.8%) developed 73 nonskin cancers, including 46 solid-organ cancers (11 renal, 11 colorectal, 7 prostate, 5 breast, 5 pancreas, 3 ovarian/endometrial/vulvar, 4 de novo cholangiocarcinoma). Twenty-two patients developed hematological malignancies (18 posttransplant lymphoproliferative diseases [PTLD], 2 Hodgkin’s disease, 2 myelodysplastic syndrome). Five patients developed melanoma. The 1-, 5-, 10- and 20-year cumulative incidences of cancer were 2.1%, 8.6%, 18.7%, and 27%, respectively. Mortality of PSC patients who developed cancer was higher than for PSC patients without cancer (HR 2.2, p<0.01). On multivariate analysis, recipient age and elevated pre-LT INR were associated with increased risk of de novo (nonskin) malignancy. CONCLUSION: The 10-year cumulative risk of cancer after LT for advanced stage PSC was 18.7%, with PTLD, colorectal and renal cell cancers being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient age and elevated INR at LT were associated with increased nonskin cancer risk.

Original languageEnglish (US)
JournalTransplantation
DOIs
StateAccepted/In press - Mar 8 2017

Fingerprint

Sclerosing Cholangitis
Skin Neoplasms
Liver Neoplasms
Liver Transplantation
Neoplasms
International Normalized Ratio
Cholangiocarcinoma
Mortality
Incidence
Kidney Neoplasms
Myelodysplastic Syndromes
Hematologic Neoplasms
Hodgkin Disease
Renal Cell Carcinoma
Prostate
Pancreas
Melanoma
Breast
Multivariate Analysis
Smoking

ASJC Scopus subject areas

  • Transplantation

Cite this

Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis. / Mouchli, Mohamad A.; Singh, Siddharth; Loftus, Jr, Edward Vincent; Boardman, Lisa Allyn; Talwalkar, Jayant; Rosen, Charles B.; Heimbach, Julie K.; Wiesner, Russell H.; Hasan, Bashar; Poterucha, John J.; Watt, Kymberly D.

In: Transplantation, 08.03.2017.

Research output: Contribution to journalArticle

Mouchli, Mohamad A. ; Singh, Siddharth ; Loftus, Jr, Edward Vincent ; Boardman, Lisa Allyn ; Talwalkar, Jayant ; Rosen, Charles B. ; Heimbach, Julie K. ; Wiesner, Russell H. ; Hasan, Bashar ; Poterucha, John J. ; Watt, Kymberly D. / Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis. In: Transplantation. 2017.
@article{3dc6a2ebfdab4e5e9977bb1ec7167a07,
title = "Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis",
abstract = "BACKGROUND: Patients with primary sclerosing cholangitis (PSC) may be at higher of risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for and long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients who underwent LT for PSC without cholangiocarcinoma from 1984-2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors and mortality from de novo malignancies after LT RESULTS: 293 patients were identified (mean age, 47±12 years; 63.3{\%} males; 2.4{\%} smoking at LT). Over a median of 11.5 years (range, 6.4-18.6), 64 patients (21.8{\%}) developed 73 nonskin cancers, including 46 solid-organ cancers (11 renal, 11 colorectal, 7 prostate, 5 breast, 5 pancreas, 3 ovarian/endometrial/vulvar, 4 de novo cholangiocarcinoma). Twenty-two patients developed hematological malignancies (18 posttransplant lymphoproliferative diseases [PTLD], 2 Hodgkin’s disease, 2 myelodysplastic syndrome). Five patients developed melanoma. The 1-, 5-, 10- and 20-year cumulative incidences of cancer were 2.1{\%}, 8.6{\%}, 18.7{\%}, and 27{\%}, respectively. Mortality of PSC patients who developed cancer was higher than for PSC patients without cancer (HR 2.2, p<0.01). On multivariate analysis, recipient age and elevated pre-LT INR were associated with increased risk of de novo (nonskin) malignancy. CONCLUSION: The 10-year cumulative risk of cancer after LT for advanced stage PSC was 18.7{\%}, with PTLD, colorectal and renal cell cancers being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient age and elevated INR at LT were associated with increased nonskin cancer risk.",
author = "Mouchli, {Mohamad A.} and Siddharth Singh and {Loftus, Jr}, {Edward Vincent} and Boardman, {Lisa Allyn} and Jayant Talwalkar and Rosen, {Charles B.} and Heimbach, {Julie K.} and Wiesner, {Russell H.} and Bashar Hasan and Poterucha, {John J.} and Watt, {Kymberly D.}",
year = "2017",
month = "3",
day = "8",
doi = "10.1097/TP.0000000000001725",
language = "English (US)",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis

AU - Mouchli, Mohamad A.

AU - Singh, Siddharth

AU - Loftus, Jr, Edward Vincent

AU - Boardman, Lisa Allyn

AU - Talwalkar, Jayant

AU - Rosen, Charles B.

AU - Heimbach, Julie K.

AU - Wiesner, Russell H.

AU - Hasan, Bashar

AU - Poterucha, John J.

AU - Watt, Kymberly D.

PY - 2017/3/8

Y1 - 2017/3/8

N2 - BACKGROUND: Patients with primary sclerosing cholangitis (PSC) may be at higher of risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for and long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients who underwent LT for PSC without cholangiocarcinoma from 1984-2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors and mortality from de novo malignancies after LT RESULTS: 293 patients were identified (mean age, 47±12 years; 63.3% males; 2.4% smoking at LT). Over a median of 11.5 years (range, 6.4-18.6), 64 patients (21.8%) developed 73 nonskin cancers, including 46 solid-organ cancers (11 renal, 11 colorectal, 7 prostate, 5 breast, 5 pancreas, 3 ovarian/endometrial/vulvar, 4 de novo cholangiocarcinoma). Twenty-two patients developed hematological malignancies (18 posttransplant lymphoproliferative diseases [PTLD], 2 Hodgkin’s disease, 2 myelodysplastic syndrome). Five patients developed melanoma. The 1-, 5-, 10- and 20-year cumulative incidences of cancer were 2.1%, 8.6%, 18.7%, and 27%, respectively. Mortality of PSC patients who developed cancer was higher than for PSC patients without cancer (HR 2.2, p<0.01). On multivariate analysis, recipient age and elevated pre-LT INR were associated with increased risk of de novo (nonskin) malignancy. CONCLUSION: The 10-year cumulative risk of cancer after LT for advanced stage PSC was 18.7%, with PTLD, colorectal and renal cell cancers being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient age and elevated INR at LT were associated with increased nonskin cancer risk.

AB - BACKGROUND: Patients with primary sclerosing cholangitis (PSC) may be at higher of risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for and long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients who underwent LT for PSC without cholangiocarcinoma from 1984-2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors and mortality from de novo malignancies after LT RESULTS: 293 patients were identified (mean age, 47±12 years; 63.3% males; 2.4% smoking at LT). Over a median of 11.5 years (range, 6.4-18.6), 64 patients (21.8%) developed 73 nonskin cancers, including 46 solid-organ cancers (11 renal, 11 colorectal, 7 prostate, 5 breast, 5 pancreas, 3 ovarian/endometrial/vulvar, 4 de novo cholangiocarcinoma). Twenty-two patients developed hematological malignancies (18 posttransplant lymphoproliferative diseases [PTLD], 2 Hodgkin’s disease, 2 myelodysplastic syndrome). Five patients developed melanoma. The 1-, 5-, 10- and 20-year cumulative incidences of cancer were 2.1%, 8.6%, 18.7%, and 27%, respectively. Mortality of PSC patients who developed cancer was higher than for PSC patients without cancer (HR 2.2, p<0.01). On multivariate analysis, recipient age and elevated pre-LT INR were associated with increased risk of de novo (nonskin) malignancy. CONCLUSION: The 10-year cumulative risk of cancer after LT for advanced stage PSC was 18.7%, with PTLD, colorectal and renal cell cancers being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient age and elevated INR at LT were associated with increased nonskin cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=85014611485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014611485&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000001725

DO - 10.1097/TP.0000000000001725

M3 - Article

C2 - 28272287

AN - SCOPUS:85014611485

JO - Transplantation

JF - Transplantation

SN - 0041-1337

ER -